Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 15, 2014
Pharmacy Choice - News - Over-the-Counter Drugs - September 15, 2014

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 6 of 6     Go To Page:

9/15/14 - Consumer Healthcare Products Association Statement on Department of Justice's Action on Supplements Claims Standards
Release date- 12092014- Washington, D.C.- The Consumer Healthcare Products Association, the trade association representing the leading makers of over-the-counter medicines and dietary supplements, released the following statement today in response to the United States Department of Justice's decision to file a motion against Bayer for claims made i
9/11/14 - Takeda And Orexigen Announce FDA Approval of Contrave Extended-release Tablets For Chronic Weight Management
Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or gre
9/11/14 - Takeda and Orexigen Announce FDA Approval of Contrave (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management
DEERFIELD, Ill., and LA JOLLA, Calif., Sept. 11, 2014/ PRNewswire/ Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight ma
9/10/14 - Enanta Reports Initiation of ABT-493 Phase 2B; Nymox Announces Positive Prostate Cancer Trial Results
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 10, 2014.{ nfg} Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced AbbVie, Enanta's development partner for protease inh
9/10/14 - Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium
WOODCLIFF LAKE, N.J. and SAN DIEGO, Sept. 10, 2014/ PRNewswire/ Eisai Inc. and Arena Pharmaceuticals, Inc. announced today that data from the Phase 3 clinical trial program for BELVIQ CIV will be presented at the American Society of Bariatric Physicians' 64 th Annual Obesity& Associated Conditions Symposium taking place September 10-13, 2014,
9/10/14 - YourEncore Launches Center of Excellence to Help Pharma Companies Meet Strict Quality Requirements
Concerns about drug quality prompted the Food and Drug Administration to create a new oversight unit in 2014. The Office of Pharmaceutical Quality was established to give more scrutiny to brand name, generic and over-the-counter drugs, especially those from overseas. "FDA data shows that pharmaceutical recalls are on the rise," said Tim Franson, M
Articles(s): 1 - 6 of 6     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415